AMARIN CORP PLC\UK Shareholders' Equity
AMARIN CORP PLC\UK (AMRN) had Shareholders' Equity of $443.62 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-29
- 2026-06-30: Stockholders' Equity Attributable to Parent $443.62M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $449.41M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $459.28M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $458.89M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $443.62M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $449.41M 10-Q · filed 2026-07-29 |
| 2025-12-31 | $459.28M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $458.89M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $464.92M 10-Q · filed 2026-07-29 |
| 2025-03-31 | $473.69M 10-Q · filed 2026-07-29 |
| 2024-12-31 | $486.18M 10-Q · filed 2026-07-29 |
| 2024-09-30 | $531.38M 10-Q · filed 2025-10-29 |
| 2024-06-30 | $551.88M 10-Q · filed 2025-10-29 |
| 2024-03-31 | $545.94M 10-Q · filed 2025-10-29 |
| 2023-12-31 | $552.10M 10-K · filed 2026-03-02 |
| 2023-09-30 | $553.15M 10-Q · filed 2024-10-30 |
| 2023-06-30 | $569.13M 10-Q · filed 2024-10-30 |
| 2023-03-31 | $584.79M 10-Q · filed 2024-10-30 |
| 2022-12-31 | $595.33M 10-K · filed 2026-03-02 |
| 2022-09-30 | $587.83M 10-Q · filed 2023-11-01 |
| 2022-06-30 | $580.04M 10-Q · filed 2023-11-01 |
| 2022-03-31 | $641.11M 10-Q · filed 2023-11-01 |
| 2021-12-31 | $667.10M 10-K · filed 2024-02-29 |
| 2021-09-30 | $642.50M 10-Q · filed 2022-10-27 |
| 2021-06-30 | $645.32M 10-Q · filed 2022-10-27 |
| 2021-03-31 | $634.61M 10-Q · filed 2022-10-27 |
| 2020-12-31 | $627.50M 10-K · filed 2023-03-01 |
| 2020-09-30 | $607.26M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $602.76M 10-Q · filed 2021-11-03 |
| 2020-03-31 | $585.78M 10-Q · filed 2021-11-03 |
| 2019-12-31 | $608.26M 10-K · filed 2023-03-01 |
| 2019-09-30 | $595.90M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $149.09M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $140.87M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $152.33M 10-K · filed 2022-03-01 |
| 2018-09-30 | -$52.83M 10-Q · filed 2019-11-05 |
| 2018-06-30 | -$46.69M 10-Q · filed 2019-11-05 |
| 2018-03-31 | -$16.66M 10-Q · filed 2019-11-05 |
| 2017-12-31 | -$65.10M 10-K · filed 2021-02-25 |
| 2017-09-30 | -$46.11M 10-Q · filed 2017-11-01 |
| 2017-06-30 | -$38.76M 10-Q · filed 2017-08-02 |
| 2017-03-31 | -$28.77M 10-Q · filed 2017-05-03 |
| 2016-12-31 | -$9.06M 10-K · filed 2020-02-25 |
| 2016-09-30 | $15.18M 10-Q · filed 2016-11-03 |
| 2016-06-30 | -$164.42M 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$156.14M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$129.19M 10-K · filed 2019-02-27 |
| 2015-09-30 | -$111.09M 10-Q · filed 2015-11-04 |
| 2015-06-30 | -$91.35M 10-Q · filed 2015-08-06 |
| 2015-03-31 | -$61.82M 10-Q · filed 2015-05-08 |
| 2014-12-31 | -$88.45M 10-K · filed 2018-02-27 |
| 2014-09-30 | -$69.24M 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$49.98M 10-Q · filed 2014-08-07 |
| 2014-03-31 | -$57.59M 10-Q · filed 2014-05-09 |
| 2013-12-31 | -$33.86M 10-K · filed 2017-03-01 |
| 2013-09-30 | -$17.70M 10-Q · filed 2013-11-07 |
| 2013-06-30 | -$94.33M 10-Q · filed 2013-08-08 |
| 2013-03-31 | -$60.09M 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$4.00M 10-K · filed 2016-02-25 |
| 2012-09-30 | $38.00K 10-Q · filed 2013-11-07 |
| 2012-06-30 | $5.32M 10-Q · filed 2013-08-08 |
| 2012-03-31 | -$64.41M 10-Q · filed 2013-05-09 |
| 2011-12-31 | -$5.96M 10-K · filed 2015-03-03 |
| 2011-09-30 | -$30.34M 10-Q · filed 2012-11-08 |
| 2011-06-30 | -$154.72M 10-Q · filed 2012-08-08 |
| 2011-03-31 | -$46.45M 10-Q · filed 2012-05-08 |
| 2010-12-31 | -$202.37M 10-K · filed 2014-02-27 |
| 2010-09-30 | -$44.94M 10-Q · filed 2011-11-08 |
| 2010-06-30 | -$39.27M 10-Q · filed 2011-08-09 |
| 2009-12-31 | $6.60M 10-K · filed 2013-02-28 |
| 2008-12-31 | $8.42M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |